These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

201 related items for PubMed ID: 19445943

  • 1. Direct-to-consumer and physician promotion of tegaserod correlated with physician visits, diagnoses, and prescriptions.
    Dorn SD, Farley JF, Hansen RA, Shah ND, Sandler RS.
    Gastroenterology; 2009 Aug; 137(2):518-24, 524.e1-2. PubMed ID: 19445943
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Tegaserod for the treatment of irritable bowel syndrome.
    Evans BW, Clark WK, Moore DJ, Whorwell PJ.
    Cochrane Database Syst Rev; 2004 Aug; (1):CD003960. PubMed ID: 14974049
    [Abstract] [Full Text] [Related]

  • 8. Effectiveness of tegaserod therapy on GI-related resource utilization in a managed care population.
    Stephenson JJ, Barghout V, Kahler KH, Fernandes J, Beaulieu JF, Joo S, Boccuzzi SJ.
    Am J Manag Care; 2005 Apr; 11(1 Suppl):S35-42. PubMed ID: 15926762
    [Abstract] [Full Text] [Related]

  • 9. Review of tegaserod in the treatment of irritable bowel syndrome.
    Patel S, Berrada D, Lembo A.
    Expert Opin Pharmacother; 2004 Nov; 5(11):2369-79. PubMed ID: 15500384
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Safety, tolerability and satisfaction with tegaserod therapy in Asia-Pacific patients with irritable bowel syndrome with constipation.
    Fock KM, Wagner A, Asia Pacific Gastroenterology Group.
    J Gastroenterol Hepatol; 2007 Aug; 22(8):1190-8. PubMed ID: 17524039
    [Abstract] [Full Text] [Related]

  • 15. [A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of tegaserod in Chinese patients with constipation-predominant irritable bowel syndrome].
    Tegaserod Clinical Research Group.
    Zhonghua Nei Ke Za Zhi; 2003 Feb; 42(2):88-90. PubMed ID: 12783702
    [Abstract] [Full Text] [Related]

  • 16. Tegaserod for constipation-predominant irritable bowel syndrome.
    Kale-Pradhan PB, Wilhelm SM.
    Pharmacotherapy; 2007 Feb; 27(2):267-77. PubMed ID: 17253916
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.